- RecruitingPHASE3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.
For: Polycythemia VeraUnited Kingdom - Ongoing, recruitingTherapeutic use (Phase IV)
HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
This study looks at how well a medicine called hydroxycarbamide works for people with a blood condition called polycythaemia vera. It aims to identify patients who might not respond well to this treatment from the beginning, helping doctors choose the best care.
For: Polycythemia veraGermany